Innovative medical device based on contactless bioinformation measurement using mmwave radar

(MaRI Co., Ltd.)



City	Year of Establishment	Founder	
Kyoto	2017	Hirofumi Taki	

Partner VC	Latest round of Fundraising	Valuation	
MedVenture Partners, Inc.	Series B	JPY 1,600 million	

Contact Information:

tel: 81-75-315-8997

e-mail: admin@marisleep.co.jp

Website:

https://sites.google.com/marisleep.app/mari/home/

O Business Plan

In order to provide a low-cost, easy-to-accept and easy-to-continue treatment for obstructive sleep apnea patients who have withdrawn from standard nasal continuous positive airway pressure (CPAP) therapy, we are developing an innovative sleep apnea treatment device based on contactless bioinformation measurement using mmwave radar and will promote its use in Japan and the United States.

Research Outline

In this project, we will establish medical evidence through domestic clinical trials. In addition, we will proceed with regulatory approval procedures in Japan and prepare for entry into the U.S. market by conducting clinical trials in the United States. Specifically, the following three items will be progressed sequentially.

- ① Improvement of basic technology and completion of prototype development for the development of mass-produced devices
- 2 Establish medical evidence and obtain regulatory approval
- 3 Conduct market research and search for collaborators and clinical trial sites in the U.S.

Business Area/Field	Research Period	Research Grant Amount	International collaborative technology demonstration
Healthcare	PCA 2024 - 2026FY	JPY 500 million	United States, Europe

OInternational collaborative technology demonstration

- Plans to conduct joint research with U.S. universities
- · Plans to establish own bases overseas
- · Plan to tie up with local partners for business development
- Plans to establish a supply chain in the U.S.

In order to expand business in the U.S., a major market, it is essential to conduct clinical studies on U.S. subjects and establish medical evidence. We plan to conduct joint research and clinical trials with Stanford University School of Medicine. After establishing medical evidence in the U.S., we plan to establish our own base in the U.S. and build a supply chain to sell medical devices in the U.S. with local medical device manufacturers.

As of April, 2024